$DBVT
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
- DBV Technologies will present new data on its VIASKIN Peanut Patch at the EAACI Congress 2026.
- Phase 3 VITESSE subgroup results in children aged 4–7 with asthma, other food allergies or atopic dermatitis showed statistically significant efficacy vs placebo, with responder rates broadly around 47% vs 15%.
- DBV will also preview the Phase 2 THRIVEstudy design in approximately 250 infants aged 6–12 months, which will evaluate ad lib peanut consumption after three years of epicutaneous immunotherapy treatment.
stocktitan.net/news/DBVT/dbv…
US HCPs: 🎤 Hear from Dr. Charles Bailey at #VAM25 as he unveils results from the #THRIVEStudy comparing #CAVT to open embolectomy in ALI.
📆 Friday, June 6
#THRIVEStudy#ALI
Rx only. Risk: peninc.info/risk Clinical results may vary.
Over half of all Canadians living with #HIV are now 50 and research into aging with HIV is more important than ever.
Check out the great presentations/resources from @PANinBC 👇, including Dr. Surita Parashar & Antonio Marante highlighting key learnings from the #ThriveStudy.
2/2
The #ThriveStudy was co-created alongside OALHIV in BC to support people during all stages of life. Learn more about how HCC obstacles can be transformed into pathways through policy & care recommendations outlined in the Thrive research report.
bccfe.ca/sites/default/files…
This week around #WorldAIDSDay, some of our BC-CfE researchers took the time to reflect on @UNAIDS' theme on ending inequalities and their own work in #HIV.
Today we hear from Dr. Surita Parashar & the #ThriveStudy focusing on older adults living w/ HIV.
bccfe.ca/blog/bc-cfe-researc…
Are you a qualified nurse working in a nursing home or care home for older people? if yes, would you like to take part in two workshops about how best to help care home nurses’ wellbeing? #thrivestudyenrich.nihr.ac.uk/supporting…